RATE OF OSTEOPOROSIS, RISK OF FRACTURES IN ELDERLY PEOPLE USING PROTON PUMP INHIBITORS

Hữu Vinh Nguyễn, Văn Trầm Tạ, Thanh Ngọc Cao, Đức Công Nguyễn

Main Article Content

Abstract

Background: Bone fractures are the most serious consequence of osteoporosis, increasing treatment costs, reducing quality of life and increasing mortality. Objective: to survey the rate of osteoporosis and the risk of bone fractures in elderly people using proton pump inhibitors at the Geriatric Clinic and Musculoskeletal Clinic of Ho Chi Minh City University of Medicine and Pharmacy Hospital. Methods: Cross-sectional study was conducted on 220 patients aged 60 years and older, continuously using proton pump inhibitors (PPIs) for ≥ 4 weeks within 6 months visiting Ho Chi Minh City University of Medicine and Pharmacy Hospital. from December 2022 to June 2023. Results: the rate of osteoporosis in the elderly using proton pump inhibitors is 52.7%, of which women and men are respectively were 55.7% and 30.8% (p = 0.017). The high risk rate of bone fractures in elderly people using proton pump inhibitors is 53.2%, in which the rates for women and men are 52.1% and 61.5% (p = 0.363). Conclusion: Prolonged use of proton pump inhibitors in the elderly increases the risk of osteoporosis, decreased bone density and increased fractures.

Article Details

References

1. E. Lespessailles, H. Toumi. Proton Pump Inhibitors and Bone Health: An Update Narrative Review. Int J Mol Sci. 2022;23.
2. J. W. Kim, S. Park, J. Y. Jung, et al. Prevalence and Factors of Osteoporosis and High Risk of Osteoporotic Fracture in Patients with Ankylosing Spondylitis: A Multicenter Comparative Study of Bone Mineral Density and the Fracture Risk Assessment Tool. J Clin Med. 2022;11.
3. L. Wang, M. Li, Y. Cao, et al. Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System. Sci Rep. 2017;7:5527.
4. M. H. Chung, Y. C. Chen, W. T. Wu, et al. Clinical Use of Lansoprazole and the Risk of Osteoporosis: A Nationwide Cohort Study. Int J Environ Res Public Health. 2022;19.
5. M. R. Fattahi, R. Niknam, M. Shams, et al. The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density. Risk Manag Healthc Policy. 2019;12:349-355.
6. Trần Thị Thanh Tú. Khảo sát chất lượng cuộc sống và các yếu tố liên quan trên bệnh nhân cao tuổi loãng xương và thiếu xương. Luận văn Thạc sĩ Y học Đại học Y Dược Thành phố Hồ Chí Minh. 2020.
7. Y. H. Shin, H. S. Gong, G. H. Baek. Lower Trabecular Bone Score is Associated With the Use of Proton Pump Inhibitors. J Clin Densitom. 2019;22:236-242.
8. Y. S. Chou, H. J. Jiang, C. H. Chen, et al. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes. Sci Rep. 2020;10:14081.